Tuesday, 9 June 2015

Mouth Ulcers Treatment Market to Exhibit 3.8% CAGR from 2014 to 2020 Due to Increasing Awareness


A new market research report has been recently published by Transparency Market Research (TMR), a U.S.-based market research and intelligence firm. The report provides a comprehensive analysis of the global mouth ulcers treatment market, along with elaborative description of the segmentation, historical data, and growth prospects of the market. The research report is titled “Mouth Ulcers Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020”.

Browse the full Mouth Ulcers Treatment MarketReport at http://www.transparencymarketresearch.com/mouth-ulcers-treatment.html


According to the research study, in 2013, the global mouth ulcers treatment market stood at US$1.2 billion and is anticipated to approach US$1.6 billion by the end of 2020, growing significantly at 3.8% CAGR between 2014 and 2020.Rising awareness among people regarding mouth ulcers and growing geriatric population are the two major factors expected to boost demand for mouth ulcers treatment in the forecast period. Asia Pacific holds considerable growth prospects for the market players. However, side-effects of mouth ulcers treatment such as constipation, blurred vision, headache, and stomach pain pose a threat to rising demand for mouth ulcers treatment products across the globe.

On the basis of formulation, the global mouth ulcers treatment market has been categorized into gel, spray, mouthwash, and lozenge. In 2013, gels held the largest share of the market, owing to the low cost of the products, easy availability at leading medical stores, and increasing preference from medical practitioners. However, the lozenges segment is anticipated to grow at a rapid pace in the forecast period. The global mouth ulcers treatment market is segmented according to indication into oral lichen planus, aphthous stomatitis, and others. Among these, in 2013, the aphthous stomatitis indication segment dominated the global mouth ulcers treatment market and is estimated to grow bearing the highest growth rate in the forecast period. The dominance of this segment was due to its growing prevalence. Furthermore, the global mouth ulcers treatment market has been segmented on the basis of drug class into antimicrobial, anesthetic, corticosteroid, analgesic, and antihistamine. In most cases, mouth ulcers do not need a particular treatment; however, if the ulcers get severe, medication is needed to reduce inflammation and pain.




The research report segments the global mouth ulcers treatments market for the purpose of geographical analysis into North America, Europe, Asia Pacific, and Rest of the World. In 2013, North America dominated the global mouth ulcers treatment market in terms of revenue and was further followed by Europe.The research report has provided a detailed analysis of the players operating in the global mouth ulcers treatment market. The analysis comprises key facts, company overview, product segmentation, business strategies, and recent development in the industry. Some of the players mentioned in the research report are Pfizer, Inc., 3M, Church & Dwight Co., Inc., Bristol-Myers Squibb Company, Taro Pharmaceutical Industries Ltd.,GlaxoSmithKline plc, BLISTEX, INC., The Colgate-Palmolive Company, and ECR Pharmaceuticals.

Request a Brochure of this Report:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Thursday, 4 June 2015

U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market Expected to Reach USD 10.2 Billion in 2020

According to a new market report published by Transparency Market Research “U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020” the U.S., Europe and Japan orthopedic soft tissue surgical procedures market was valued at USD 7.3 billion in 2013 and is estimated to reach a market worth of USD 10.2 billion in 2020 growing at a CAGR of 4.9% from 2014 to 2020.

Browse the full U.S., Europe and Japan Orthopedic Soft Tissue Surgical Procedures Market report at http://www.transparencymarketresearch.com/soft-tissue-repair-sports-medicine.html


The report on U.S., Europe and Japan orthopedic soft tissue surgical procedures market studies market size of rotator cuff repair, vaginal prolapse, lateral epicondylitis, achilles tendinosis repair, gluteal tendon repair and anterior cruciate ligament reconstruction (ACL). Rising number of sport related injuries coupled with growth of active aging population in the developed regions would boost the demand of orthopedic soft tissue surgeries. According to the American Academy of Orthopaedic Surgeons (AAOS) and the American Orthopaedic Society for Sports Medicine, over 150,000 anterior cruciate ligament (ACL) injuries occur each year in the U.S. alone. Additionally, introduction of high cost and innovative surgical repair products and increasing incidence of obesity have raised the demand of orthopedic surgeries thereby propelling market growth. For example, Biomet, Inc. launched JuggerKnotless Soft Anchor device in July 2014 which featured company’s all-suture anchor technology. This device enables the repair of rotator cuff damage with better restoration and high efficacy. Growing acceptance of minimally invasive soft tissue surgical techniques (arthroscopy procedures) has enabled the completion of soft tissue surgeries in shorter time with lesser complication rates. This factor is also increasing the uptake of soft tissue surgeries. However, asymptomatic nature of soft tissue surgeries and high threat from conservative therapy are anticipated to restrain the market growth.

In terms of various surgical procedures ACL reconstruction accounted for the largest share of the market in 2013. ACL reconstruction is also likely to retain its dominant position in the future as it is the most common knee injury that requires surgical intervention. Rising participation in sports such as football, basketball and others along with increasing number of patients opting for reconstructive surgeries due to introduction of minimally invasive surgeries would fuel the growth of this segment. Similarly, launch of bio-absorbable which nullifies the risk related to implant removal would also aid in increasing the market size for ACL reconstruction. The market of gluteal tendon repair accounted for the smallest share in 2013 owing to large pool of patients being treated by non-operative methods such as pain killers and steroid injection for this condition.
Browse the full Press Release Report:

soft-tissue-repair-sports-medicine-market

Geographically, the U.S. orthopedic soft tissue surgical procedures market captured major market revenue in 2013 and is expected to dominate the market during the forecast period from 2014 to 2020. Rising population base, increasing urge to stay healthy among geriatric population and improving healthcare coverage would contribute towards the growth of orthopedic soft tissue surgical procedures in this region. The orthopedic soft tissue surgical procedures market in Europe is anticipated to grow at a CAGR of 4.7% due to increasing number of sports related injuries. According to “Injuries in the European Union” published by EuroSafe, sports related injuries accounted for around 14% of the total injuries in the European Union. Similarly, a survey conducted by the professionals in Europe in 2010 concluded that the annual prevalence of people consulting for shoulder pain was 2.4% in the U.K.; most of these were attributed to rotator cuff injuries. Thus, increasing incidences of soft tissue injuries would propel the market growth in this region.

The orthopedic soft tissue surgical procedures market is fragmented in nature and is dominated by players, namely Arthrex, Inc., Smith & Nephew, plc., DePuy Synthes, Inc., Stryker Corporation., CONMED Corporation, and ArthroCare Corporation. Of all these, Arthrex was identified as the largest player in this market in 2013 followed by Smith & Nephew and Depuy Synthes, Inc.


The U.S., Europe and Japan orthopedic soft tissue surgical procedures market is segmented as follows:
U.S. Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction
Europe Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction
Japan Orthopedic Soft Tissue Surgical Procedures Market, by Indications
Rotator Cuff Repair
Vaginal Prolapse
Lateral Epicondylitis
Achilles Tendinosis Repair
Gluteal Tendon Repair
Anterior Cruciate Ligament (ACL) Reconstruction


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

 Website: http://www.transparencymarketresearch.com/

Albumin (Excipient) Market Expected to Reach USD 0.8 Billion Globally in 2020

According to a new market report published by Transparency Market Research “Albumin (Excipient) Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends and Forecast, 2014 - 2020,” the global albumin excipient market was valued at USD 704.9 million in 2013 and is expected to grow at a CAGR of 2.3% from 2014 to 2020, to reach an estimated value of USD 828.2 million by 2020.

Browse the full Albumin (Excipient) Market Report at http://www.transparencymarketresearch.com/albumin-market.html


Selection of appropriate excipients is very important during the development of drug formulations and vaccines. A suitable excipient helps stabilize and protect an active pharmaceutical ingredient (API) in the formulation against degradation, oxidation or aggregation that the API could undergo during manufacturing, transport and storage. As an excipient, albumin has wide applications in drug formulation, drug delivery, vaccine manufacturing and as a component of media for the production of vaccines. Manufacturers are increasingly considering innovative ways to reduce contamination risks of finished products due to the recent incidents of animal virus contamination of biopharmaceutical products. Manufacturers must adhere to strict regulations on the standards and also provide detailed information on the country of origin (BSE free), the types of tissue used and details of the manufacturing process during the compliance and approval procedure.

The global albumin market is analyzed by albumin type, applications and geography. On the basis of type, the market is segmented into human serum albumin, bovine serum albumin and recombinant albumin. Human serum albumin was the largest segment and was valued at USD 476.7 million in 2013. The segment is expected to reach USD 557.0 million in 2020, growing at a CAGR of 2.2% during the forecast period between 2014 and 2020. Bovine serum albumin is used in the production of vaccines such as MMR II, Varivax, Zostavax and RotaTeq in ranges of less than 1 ppm. Extensive research to explore new ways is underway to increase virus yield and quality in manufacturing. Recently, end-user preference has been observed to have shifted towards recombinant human albumin (rAlbumin) used in multiple applications such as in nano formulation and drug carrier over specific therapeutic modalities. Advances in yeast-based protein expression and the successful scale-up have led to the development of an industrial-scale manufacturing process that can produce a highly pure, animal-free rAlbumin suitable for use as an excipient in biotherapeutics.

albumin-market

Primary applications of albumin include drug formulation and drug delivery, vaccines, and component of media. The drug formulation and drug delivery segment is expected to reach USD 395.9 million in 2020. Expansion of the role of albumin in drug delivery has widened the field of nanotechnology as well. For instance, Abraxis BioScience has applied nanotechnology to human serum albumin (HSA) with its nanoparticle albumin-bound, known as ‘NAB’ technology platform. This approach combines HSA with an API for delivering protein drugs.

Geographically, North America continues to dominate the market due to high demand for albumin in drug formulations, and research and development activities. The albumin market in the region was valued at USD 253.8 million in 2013. The current focus of the research community in most of the academic institutions and industry is to use albumin as a carrier for micro- and nanoparticles for sustained-release injectable drugs. Paclitaxel nano-particulate formulation containing albumin as a carrier was approved by the U.S. FDA in September 2013. Countries such as China, India and Australia exhibit significant growth prospects in terms of rapid increase in the research collaboration between industry and research institutions. GlaxoSmithKline Pharmaceuticals Limited (GSK) is funding around USD 4 million per year to initiate research and development program with the leading research institutions in Asia Pacific for the development of potential therapeutics.


Some of the major companies operating in the global albumin market are CSL Behring, HiMedia, InVitria, Mitsubishi Tanabe Pharma, Octapharma AG, Novozymes A/S, Raybiotech, Inc., Sigma-Aldrich Corporation, Thermo Fischer Scientific, Inc. and MedxBio Pte. Ltd. Pharmaceutical companies and research institutes obtain the desired albumin excipient grade from the market players for their development activities. The key players in the global albumin market improve their distribution network by entering into strategic alliances and distributorship agreements. For instance, InVitria partnered with Thermo Fischer Scientific and Sigma-Aldrich in order to provide its customers with product support best tailored to meet their needs. InVitria has distributors across the world including North America, Europe, Asia and Australia.


The global albumin market is segmented as follows:
Albumin Market Revenue (USD Million), by Type
Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin
Albumin Market Revenue (USD Million) and Volume (kg), by Application
Drug Formulation and Drug Delivery
Vaccines
Component of Medium
Albumin Market Revenue (USD Million) and Volume (kg), by Geography
North America
Europe
Asia Pacific
Rest of the World



About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com


Global Tuberculosis Testing Market Finds Encouragement in Growing Healthcare Efforts

The global tuberculosis testing market continues to grow as governments and institutions across the globe continue to make efforts to eradicate this deadly communicable disease. Statistics gathered by the WHO state that 9 million people acquired tuberculosis (TB) in 2013 and 1.5 met a fatal end, out of which 360,000 were HIV positive. These figures are declining with each passing year thanks to the increasingly effective diagnosis and treatment options offered to patients. It is estimated that such initiatives were able to save the lives of 37 million tuberculosis patients between 2000 and 2013.

Browse Full Global Tuberculosis Testing Market Report With Complete TOC @ http://www.transparencymarketresearch.com/tuberculosis-testing-market.html


Tuberculosis can be broken down into two types, namely active disease, which can transform to multi-drug resistant TB or MDR-TB, and latent disease. Tuberculosis also has a rare form called miliary TB, which occurs when TB infection finds its way to the bloodstream. The priority steps to counter MDR-TB are supreme quality of treatment for drug-susceptible TB to avert MDR-TB, expanding the reach of testing and detection of MDR-TB cases to remote regions, simplifying the access to good healthcare, infection control, and strengthening the political commitment, especially in BRIC nations, which constitute 50% of global TB cases.
Dedicated Efforts of Non-profit Organizations Drive Global Tuberculosis Testing Market
The efforts taken by governments, social activists, and several healthcare institutions have translated into positive results. A ripple effect of these efforts can also be seen in the growth of the global tuberculosis testing market. The global tuberculosis testing market was worth US$1,936.1 million in 2013. By 2020 this market is expected to reach a valuation of US$2,619.4 million, growing at a promising CAGR of 4.3% from 2014 to 2020.

The factors driving this gigantic growth are the rising number of tuberculosis cases, increasing acceptance of innovative methods for treating tuberculosis, and enhanced molecular and rapid culture diagnostic tests. The serious involvement and dedicated efforts of non-profit healthcare organizations are further boosting the global tuberculosis testing market. Growing tuberculosis cases have also resulted in increased research and development budgets, encouraging manufacturers to launch better testing technologies.



Serological Tests and IGRA Sub-segments to Grow the Fastest

The global tuberculosis testing market is classified on the basis of type and geography. The segments by product type are culture-based tests, smear microscopy, nucleic acid testing, radiography (chest x-ray), Mantoux test (tuberculin skin test), drug susceptibility test (DST), and other tests such as serological tests, ADA, and IGRA. Geographically, the global tuberculosis testing market is fragmented into North America, Asia Pacific, Europe, and Rest of the World.

Out of these segments, culture-based tests hold a lion’s share in the global tuberculosis testing market. These tests are inclusive of both solid and liquid culture tests. Analysts predict that other segments such as serological tests and IGRA will grow rapidly in the coming five years as well. All of these tuberculosis testing methods generate quick results, offer improved accuracy, and require the patient to just one visit.

India and China to Make Steady Contribution to Growth of Global Tuberculosis Market

Geographically, Asia Pacific led the global tuberculosis testing market in 2013, closely followed by North America. The prime factor driving the unprecedented growth rate in Asia Pacific is a huge patient pool, which continues to grow at a rapid rate, especially in countries such as China and India. Though North America has a smaller patient pool, the tuberculosis testing market is expected to grow in this region due to increasing awareness, better healthcare infrastructure, and growing acceptance and adoption of expensive TB tests due to improving purchasing power of patients.

Some of the key players in the global tuberculosis testing market are Akonni Biosystems Inc., Abbott Laboratories, Becton, Alere Inc., Dickinson and Company, Cepheid, Epistem plc, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, QIAGEN, Hain Lifescience GmbH, Sanofi, and Thermo Fisher Scientific Inc.


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Growing Incidence of Congestive Heart Failure Drives Global Dilated Cardiomyopathy Therapeutics Market


Dilated cardiomyopathy is a condition strongly related to heart attacks, in which the ventricles are enlarged, resulting in a thinning of cardiac walls, and insufficient pumping of blood. Dilated cardiomyopathy can occur at any age, though it is most common in the 20-40 demographic. One of the major reasons of dilated cardiomyopathy is genetic. Some other factors that can cause dilated cardiomyopathy are thyroid disorders, viral infections of the heart, diabetes, alcoholism, and heart valve malformations.

Browse Full Global Dilated Cardiomyopathy Therapeutics Market Report With Complete TOC @ http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html


Angiotensin II Receptor Blockers Held Largest Share of Dilated Cardiomyopathy Therapeutics Market in 2013 by Revenue

The dilated cardiomyopathy therapeutics market worldwide is segregated on the basis of drug class, pipeline drugs, and geography. The dilated cardiomyopathy therapeutics market globally in terms of drug class is broadly classified as angiotensin-converting enzyme (ACE) inhibitors, beta blockers, aldosterone antagonists, and angiotensin II receptor blockers (ARBs). Of all the drug class, angiotensin II receptor blockers held the largest share of the dilated cardiomyopathy therapeutics market in 2013 by revenue, followed by beta blockers.

The high demand for the leading drugs for the treatment of dilated cardiomyopathy from developed regions such as Europe and North America is a reason for the large market shares of these classes of drugs. When used in combination either with ACE or ARBs, aldesterone antagonist drugs have proven to have a positive impact on the reduction of progressive conditions such as Duchenne muscular dystrophy (DMD).

The global dilated cardiomyopathy therapeutics market was worth US$651.0 million in 2013. By 2020, the global dilated cardiomyopathy therapeutics market is projected to be worth US$328.6 million which shows a decline of 7% CAGR from 2014 to 2020.

Clinical Trials May Halt Expected Reduction of Dilated Cardiomyopathy Therapeutics Market

The dilated cardiomyopathy therapeutics market worldwide is driven by growing incidence of congestive heart failure which is significantly related with DCM. On a global scenario, dilated cardiomyopathy is associated to 30% to 40% for congestive heart failure cases every year. Due to the growing incidence of congestive heart failure worldwide, several companies have initiated clinical trials for the advancement of therapeutics for dilated cardiomyopathy.

Some of the clinical trials undertaken are a phase II study by Array BioPharma in 2015 for its drug class ARRY-371797, a phase II study by Celladon Corporation in 2014 for its drug class MYDICAR. The dilated cardiomyopathy therapeutics market is expected to get a boost on the successful completion of these clinical trials. However, implantable devices such as heart pumps, pacemakers, and advancement in gene therapy will restrain the growth of dilated cardiomyopathy therapeutics market.

Browse Full Press Release Report :

North America Leads Global Dilated Cardiomyopathy Therapeutics Market

According to geographical segmentation, the dilated cardiomyopathy therapeutics market is divided into four regions, which are Asia Pacific, Europe, North America, and Rest of the World (RoW). North America held the largest share of the dilated cardiomyopathy therapeutics market in 2013 owing to rising cases of heart diseases and acceptance for branded drugs.

The U.S. and Canada make up the dilated cardiomyopathy therapeutics market in North America. The prevalence of DCM in the U.S. is high; 5-8 people out of every 100,000 are diagnosed with DCM. In Canada, heart failure accounts for 9% of total deaths in the country, which is driving the dilated cardiomyopathy therapeutics market in North America.

In Europe, countries such as Spain, Germany, the U.K., and Italy contribute significantly towards the growth of the dilated cardiomyopathy therapeutics market. The dilated cardiomyopathy therapeutics market is growing in Asia Pacific and Rest of the World (RoW) owing to rising economic power, higher incomes, and growing demand for generic drugs.

Some of the key players in the dilated cardiomyopathy therapeutics market are Teva Pharmaceutical Industries Ltd , Merck & Co., Inc., Array BioPharma, Inc., Celladon Corporation, GlaxoSmithKline plc, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., AstraZeneca plc and Vericel Corporation.


About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Wednesday, 3 June 2015

Collagen Peptide and Gelatin Market: APAC to Emerge as Most Lucrative Region Owing to Rising Health Awareness


Surging awareness about physiological well-being and personal healthcare drives the growth of the global collagen peptide and gelatin market, states a recently published report by Transparency Market Research. The report is titled “Collagen Peptide and Gelatin Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecast, 2014 - 2020” and is available for sale on the company website.According to the report, the global collagen peptide market is poised to grow from US$0.7 billion in 2013 to US$1.1 billion in 2020, registering a 6.8% CAGR during the forecast period. The gelatin market, on the other hand, was worth US$1.8 billion in 2013 and is estimated to be worth US$3.0 billion by 2020, developing at a 7.5% CAGR from 2014 to 2020.

Browse the full Collagen Peptide and Gelatin Market Report at http://www.transparencymarketresearch.com/collagen-peptide.html


The collagen peptide and gelatin market is segmented on the basis of type of sources, applications, and geography. Geographically, the global collagen peptide and gelatin market is divided into North America, Europe, Asia Pacific, and Rest of the World. Owing to the increased popularity of cosmeceuticals, rise in R&D activities, and growing awareness about nutraceuticals, North America dominated the collagen peptide market in 2013. The gelatin market, however, was led by Europe owing to flourishing pharmaceutical and food and beverages industries and presence of several research organizations in the field of nutritional products. The Asia Pacific market for collagen peptide and gelatin is set to be the most promising regional segment from 2014 to 2020 owing to rising importance of nutrition and personal well-being and steady pace of industrialization.
The key sources of gelatin are chicken, porcine, marine, bovine, and others such as donkey, horse, cat, and dog. The major applications areas of gelatin are pet food, cosmeceuticals, food and beverages, ballistics, bone and joint health, pharmaceuticals, nutraceuticals, photography, and India ink. Porcine gelatin led the global market, with marine gelatin likely to register the highest CAGR over the forecast period. By application, the use of gelatin in the food and beverages segment held the largest share of the market, with bone and health being the fastest growing application segment from 2014 to 2020.Marine collagen peptide was the largest as well as the most rapidly developing segment in 2013 and is estimated to retain its lead during the course of the forecast period. Cosmeceuticals was the dominant segment of the collagen peptide market in terms of application and it held a 20% share in the global market. However, the use of collagen peptide in applications such as wound healing and regenerative medicine will be the fastest growing segment by 2020.

Browse the full Press Release Report :

The collagen peptide and gelatin market is rather consolidated, with a select few players dominating the global market. The major players featured in the collagen peptide and gelatin market report are ChinaTech Peptide Co. Ltd., Nitta Gelatin, Inc., Sterling Gelatin, BioCell Technology LLC, InterHealth Nutraceuticals, Inc., Capsugel Belgium NV, Roxlor LLC, Weishardt International Group, GELITA AG, Norland Products, Inc., Pont Brule (PB) Gelatins GmbH, Amicogen, Inc., Catalent, Inc., and Rousselot International. Among these, GELITA AG dominated by gelatin market in 2013, while Rousselot International led the collagen peptide market the same year.



About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Active Pharmaceutical Ingredients Market Growing at a CAGR of 6.5% between 2014 and 2020

Diseases and epidemics are nature’s way to control population. With the ever-increasing number of deaths being reported due to various chronic diseases as well as newly diagnosed cases, the global active pharmaceutical ingredients (API) market has a huge demand to meet.

Browse Full Global Active Pharmaceutical Ingredients Market Report With Complete TOC @ http://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html


Global API Market to be Valued at US$185.9 Billion by 2020

In 2013, the global API market was valued at US$119.7 billion. It is expected to grow at a CAGR of 6.5% from 2014 to 2020 and reach a valuation of US$185.9 billion by 2020. On the basis of therapeutic area, the API market is segmented into non-steroidal anti-inflammatory drugs (NSAIDS), oncology drugs, anti-diabetic drugs, cardiovascular drugs, central nervous system drugs, musculoskeletal drugs, and others.

Oncology Segment Will Be the Fastest Growing Drug Segment

Due to the prevalent sedentary lifestyle and growing aging population, cardiovascular diseases and diseases related to the central nervous system are rising. In 2013, the market revenue share for cardiovascular drugs was the highest. As per the data provided by the World Health Organization, in 2012, cancer alone led to 8.2 million deaths worldwide along with 14 million newly diagnosed cases. In response to this, the oncology drug segment will have the fastest growth in the API market during the period from 2014 to 2020. High potency active pharmaceutical ingredients (HPAPIs) are a component of most drugs in the oncology drug segment. So, the growth of the HPAPI market would be rapid to keep up with the growth of oncology drug segment.

Asia Pacific will Account for the Highest Growth from 2014 to 2020

In 2013, North America accounted for the majority share (35%) in the global API market. The API market in this region is expected to grow further. FDA approvals for the production of innovative drugs and growing awareness about the intake of generic medicines have led to the growth of the API market in North America.

The Asia Pacific region is expected to achieve the highest growth in the global API market in the period from 2014 to 2020. The API market has a huge demand from the Asia Pacific region because of the population demographics in this geography. In terms of production, the global API market has shifted to Asia Pacific because of the availability of cheap labor, tax benefits provided by the governments for manufacturing, and less regulations on the markets.

China and India are the frontrunners in API production. API manufacturing companies from North America and Europe have invested substantially in these two countries. In North America, stringent pharmaceutical regulations, such as the U.S. Drug Quality and Security Act, have to be met with. This has caused a slight decrease in the growth of the API market in this region.

Browse Full Press Release Report:


Costlier Production of Biological Drugs Hampers Segment

Compared to synthetic APIs, biological drugs are costlier because they are difficult to replicate and have difficult manufacturing requirements. Enhanced technological support has resulted in the production of biosimilars, which are not the exact replication of innovator drugs, but are efficient and safe. This has led to a big opportunity for biopharmaceutical companies like Novartis in the API market.

However, production of biosimilars requires approvals from the respective countries. The European Union has set the trend by approving biosimilars and the WHO has followed the approval guidelines similar to the European Union. As a first, the U.S. has approved the biosimilar Filgrastim (2015), which shows its interest in expanding its biological API market.

Key Players in Active Pharmaceutical Ingredients Market

The key players competing in the global API market include Cambrex Corporation, Boehringer Ingelheim Group, Pfizer Inc., Dr. Reddy’s Laboratories Ltd., BASF SE, Hospira Inc., Lonza Group, Mylan, Inc., Novartis AG, Actavis plc, Teva Pharmaceutical Industries Ltd., and Wuxi Apptec.

Request a Brochure of this Report

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com